Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations

• eyonis™ (formerly known as iBiopsy®) scientific poster presentation: End-to-End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis
• Imaging Lab scientific poster presentation: A CT Imaging Biomarker for CD8+ Lymphocytes Infiltration Stratification in Patients with Non-Small Cell Lung Cancer
• Median’s eyonis™ and Imaging Lab teams will attend the event and be available after poster sessions for presenting the latest advances of eyonis® AI/ML tech based SaMD and the Imaging Lab developments.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:

Median Technologies (Paris:ALMDT) announced today that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being held in Chicago (Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3. The NACLC is organized by the International Association for the Study of Lung Cancer (IASLC), a global multidisciplinary association dedicated to eradication of all forms of lung cancers.

The Company will give two poster presentations on December 2^nd from 5:40 to 6:55 pm CT.

Poster PP01.49: End to End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis

Poster PP01.44: A CT Imaging Biomarker for CD8+ Lymphocytes Infiltration Stratification in Patients with Non-Small Cell Lung Cancer

Median’s eyonis™ and Imaging Lab teams will attend the event and be available for presenting the latest advances of eyonis® AI/ML tech based SaMD and the Imaging Lab developments.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™ (formerly known as iBiopsy®), our AI/ML tech-based suite of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com